Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery disease
| Autor: | Wes Pedersen, Fredarick L. Gobel, Irvin F. Goldenberg, Adrian K. Almquist, Robert P. Ochi, Simon Milstein, David G. Benditt, Marc R. Pritzker |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Amiodarone Coronary Disease Ventricular tachycardia Coronary artery disease Refractory Tachycardia Internal medicine medicine Humans Infusions Intravenous Chemotherapy Ejection fraction business.industry Middle Aged medicine.disease Anesthesia Ventricular Fibrillation Ventricular fibrillation Cardiology Female Cardiology and Cardiovascular Medicine Cardioversions business Follow-Up Studies medicine.drug |
| Zdroj: | The American Journal of Cardiology. 64:599-603 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/0002-9149(89)90486-4 |
| Popis: | This study examined the effectiveness of intravenous amiodarone for rapid control and prevention of recurrent life-threatening ventricular tachyarrhythmias associated with cardiovascular collapse. In 22 critically ill patients with coronary artery disease (mean ejection fraction 27 +/- 13%), recurrent ventricular tachyarrhythmias proved refractory to 3.7 +/- 1.1 (mean +/- standard deviation) conventional antiarrhythmic drugs. In the 24-hour period before intravenous amiodarone treatment, patients experienced 2.4 +/- 2.3 (range 1 to 9) episodes of life-threatening ventricular tachycardia, ventricular fibrillation or both, requiring 4.0 +/- 3.9 direct current cardioversions. Within the 24 hours after initiation of intravenous amiodarone therapy (900 to 1,600 mg/day), 20 of 22 patients remained alive and had 1.1 +/- 1.6 episodes of life-threatening ventricular arrhythmias, requiring 1.9 +/- 3.1 direct current cardioversions. In the second 24-hour period, there were 19 survivors and life-threatening arrhythmias were reduced to 0.4 +/- 0.7 episode/patient requiring 0.4 +/- 0.9 direct current cardioversion. Overall, arrhythmias were controlled in 11 of 22 (50%) patients within the first 24 hours, and in 14 of 22 (64%) in the second 24 hours. Intravenous amiodarone therapy was well tolerated. Twelve patients were discharged from the hospital and 8 remained alive at a mean follow-up of 22 +/- 14 months. Thus, in critically ill patients, intravenous amiodarone may be useful for rapid control of spontaneous, refractory, life-threatening ventricular tachyarrhythmias. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|